[ECTE] Echo Therapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus

Market Capitalization: 15.84 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 0.22 Change: 0 (0.05%)
Ext. hours: Change: 0 (0%)

chart ECTE

Refresh chart

Strongest Trends Summary For ECTE

ECTE is in the medium-term up 297% above S&P in 1 month. In the long-term down -100% below S&P in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Echo Therapeutics, Inc. is engaged in the development of transdermal skin permeation and diagnostic medical devices. It is developing Symphony CGM system (Symphony), a needle-free wireless continuous glucose monitoring system for use in hospital critical care units; and Symphony SkinPrep system, a component of its Symphony for enhanced skin permeation that enables extraction of analytes, such as glucose. The company is also engaged in the development Durhalieve, an AzoneTS formulation of triamcinolone acetonide that has completed Phase III clinical trials for the treatment of corticosteroid-responsive dermatoses. It has a licensing agreement with Ferndale Pharma Group, Inc. to develop, market, sell, and distribute Prelude SkinPrep system for skin preparation prior to the application of topical anesthetics prior to a range of needle-based medical procedures in North America, the United Kingdom, South America, Australia, New Zealand, Switzerland, and other portions of the European Community; a license agreement

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding11.48 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV3.29 Price/Cash Per Share
Price/Free Cash Flow-1.91 ROA-176.63% ROE-327.84% ROI
Current Ratio0.17 Quick Ratio Long Term Debt/Equity Debt Ratio0.84
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities1000 K Cash From Investing Activities-60 K Cash From Operating Activities-1.74 M Gross Profit
Net Profit-8.3 M Operating Profit-2.51 M Total Assets11.6 M Total Current Assets920 K
Total Current Liabilities5.26 M Total Debt Total Liabilities5.35 M Total Revenue
Technical Data
High 52 week0.01 Low 52 week Last close0.01 Last change110%
RSI85.25 Average true range Beta0.28 Volume16.16 K
Simple moving average 20 days158.2% Simple moving average 50 days271.9% Simple moving average 200 days61.89%
Performance Data
Performance Week117.24% Performance Month530% Performance Quart26% Performance Half5%
Performance Year-11.27% Performance Year-to-date800% Volatility daily33.47% Volatility weekly74.83%
Volatility monthly153.36% Volatility yearly531.27% Relative Volume56.06% Average Volume25.14 K
New High New Low

News

2016-12-27 06:03:29 | ECHO THERAPEUTICS, INC. Files SEC form 8-K, Other Events

2016-12-21 12:54:00 | Echo Therapeutics Announces Dismissal of Federal Court Action

2016-12-14 13:09:47 | ECHO THERAPEUTICS, INC. Files SEC form 8-K, Other Events

2016-12-12 14:12:00 | Echo Therapeutics Announces Federal Court's Denial Of Preliminary Injunction And Lifting Of Temporary Restraining Order

2016-12-06 19:44:00 | /C O R R E C T I O N -- Manchester Management LLC/

2016-12-01 14:28:00 | 2:28 pm Echo Therapeutics announces they were informed by BDO USA that BDO was resigning as the co's independent registered public accounting firm

2016-11-16 14:29:17 | ECHO THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report

2016-10-19 15:02:41 | ECHO THERAPEUTICS, INC. Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an Off-B

2016-09-23 17:04:37 | ECHO THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financia

2016-08-20 13:04:23 | ECHO THERAPEUTICS, INC. Financials

2016-08-15 13:41:06 | Echo Therapeutics, Inc. Announces Second Quarter 2016 Financial Results

2016-08-12 14:44:00 | Echo Therapeutics, Inc. Announces Second Quarter 2016 Financial Results

2016-08-12 14:36:32 | ECHO THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report

2016-07-12 12:35:04 | Echo Therapeutics Delisted from Nasdaq, Shares Plummet

2016-07-08 20:21:06 | Echo Therapeutics Common Stock to Transition from NASDAQ to OTCQB

2016-07-08 16:26:00 | Echo Therapeutics Common Stock to Transition from NASDAQ to OTCQB

2016-07-08 16:13:18 | ECHO THERAPEUTICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta

2016-07-05 09:57:32 | Platinum Partners to Shut Down Main Fund; Here Are Its 5 Stock Picks

2016-06-29 19:11:04 | Echo Therapeutics Begins Testing of NextGen CGM System Components

2016-06-29 07:50:00 | Echo Therapeutics Begins Testing of NextGen CGM System Components

2016-06-23 02:09:11 | Echo Therapeutics Announces New Patent for its Non-Invasive Sensing Technology

2016-06-22 09:02:44 | Echo Therapeutics Gets Fresh Patent For Non-Invasive Sensing Technology

2016-06-22 07:50:00 | Echo Therapeutics Announces New Patent for its Non-Invasive Sensing Technology

2016-06-15 03:19:08 | Echo Therapeutics Announces Institutional Review Board IRB Approval of New Protocol

2016-06-13 07:50:00 | Echo Therapeutics Announces Institutional Review Board IRB Approval of New Protocol

2016-06-03 10:13:58 | ECHO THERAPEUTICS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financia

2016-06-02 17:45:09 | Echo Therapeutics in Final Stage of Clinical Research Organization CRO Selection

2016-06-02 08:27:15 | Echo Therapeutics Says It's In Final Stage Of Clinical Research Organization Selection

2016-06-02 07:50:00 | Echo Therapeutics in Final Stage of Clinical Research Organization CRO Selection

2016-05-26 15:11:45 | ECHO THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders

2016-05-21 11:43:02 | Echo Therapeutics, Inc. Announces First Quarter 2016 Financial Results

2016-05-20 11:34:00 | Echo Therapeutics, Inc. Announces First Quarter 2016 Financial Results

2016-05-20 11:21:35 | ECHO THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report

2016-05-17 11:12:06 | Echo Therapeutics Announces Final Closing of Private Placement of $5.1 Million of Convertible Notes and Warrants

2016-05-17 11:12:06 | Echo Therapeutics Announces Successful Software Transfer to its Strategic Partner, MTIA

2016-05-17 07:50:00 | Echo Therapeutics Announces Successful Software Transfer to its Strategic Partner, MTIA

2016-05-06 16:05:00 | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation into Possible Violations of Delaware Law by Certain Officers and Directors of Echo Therapeutics, Inc.

2016-05-04 16:11:00 | Echo Therapeutics Announces Final Closing of Private Placement of $5.1 Million of Convertible Notes and Warrants

2016-05-04 10:00:08 | Echo Therapeutics Announces Significant Progress in Key Development Milestones

2016-05-03 09:42:00 | Echo Therapeutics Announces Significant Progress in Key Development Milestones

2016-04-28 11:40:02 | Echo Therapeutics Announces Conference Call to Provide an Update on Corporate Milestones

2016-04-26 10:55:59 | Echo Therapeutics Announces Voting Results of Special Meeting of Stockholders

2016-04-14 16:30:00 | Echo Therapeutics Announces Voting Results of Special Meeting of Stockholders

2016-03-31 12:49:07 | Echo Therapeutics, Inc. Announces 2015 Financial Results

2016-01-04 14:19:28 | Echo Therapeutics Appoints Elazer Edelman, M.D., Ph.D. to Board of Directors

2015-12-09 03:31:13 | Echo Therapeutics, Inc. Announces Third Quarter 2015 Financial Results and Provides Corporate Update